---
title: "uniQure to Announce Second Quarter 2026 Financial Results | QURE Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293463630.md"
description: "uniQure N.V. (NASDAQ: QURE) will report its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results. The event will be webcast on the company's website, and a replay will be available for 90 days. Analysts can join the Q&A session via phone using the provided dial-in numbers and conference ID."
datetime: "2026-07-22T03:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293463630.md)
  - [en](https://longbridge.com/en/news/293463630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293463630.md)
generator: "portal-rs"
---

# uniQure to Announce Second Quarter 2026 Financial Results | QURE Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

**\~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~**

LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

**About uniQure** 

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

**uniQure Contacts:**

**FOR INVESTORS:**

**FOR MEDIA:**

**Chiara Russo**

**Tom Malone**

Direct: 781-491-4371

Direct: 339-970-7558

Mobile: 617-306-9137

Mobile:339-223-8541

c.russo@uniQure.com

t.malone@uniQure.com

### Related Stocks

- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)

## Related News & Research

- [uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease | QURE Stock News](https://longbridge.com/en/news/297775517.md)
- [uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says](https://longbridge.com/en/news/297819704.md)
- [A Look At uniQure (QURE) Valuation After Strong Recent Share Price Gains](https://longbridge.com/en/news/288346961.md)
- [Walid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) Stock](https://longbridge.com/en/news/291590037.md)
- [Regenxbio, Replimune among gainers after FDA U-turn on UniQure](https://longbridge.com/en/news/290092762.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**